Foster & Motley Inc. Buys Shares of 10,650 Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Foster & Motley Inc. acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,650 shares of the biopharmaceutical company's stock, valued at approximately $609,000.

A number of other hedge funds have also recently bought and sold shares of the company. Catalyst Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $1,944,000. QRG Capital Management Inc. bought a new position in Halozyme Therapeutics during the third quarter worth about $245,000. Janney Montgomery Scott LLC raised its position in shares of Halozyme Therapeutics by 38.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 36,020 shares of the biopharmaceutical company's stock valued at $2,062,000 after acquiring an additional 9,995 shares during the period. VELA Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $729,000. Finally, James Investment Research Inc. increased its position in shares of Halozyme Therapeutics by 37.3% in the 3rd quarter. James Investment Research Inc. now owns 29,075 shares of the biopharmaceutical company's stock valued at $1,664,000 after buying an additional 7,903 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In related news, Director Matthew L. Posard sold 10,000 shares of the business's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $55.72, for a total value of $557,200.00. Following the completion of the sale, the director now directly owns 89,755 shares in the company, valued at $5,001,148.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the business's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.72, for a total value of $557,200.00. Following the completion of the sale, the director now owns 89,755 shares of the company's stock, valued at $5,001,148.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares of the company's stock, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,881 shares of company stock worth $5,169,834. Insiders own 2.70% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $1.33 on Friday, reaching $60.98. The stock had a trading volume of 1,109,682 shares, compared to its average volume of 1,288,004. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm's 50-day moving average is $56.67 and its two-hundred day moving average is $52.53. The firm has a market capitalization of $7.76 billion, a price-to-earnings ratio of 20.19, a P/E/G ratio of 0.53 and a beta of 1.29. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.18. The business had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 179.82% and a net margin of 41.43%. The company's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.68 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research analyst reports. Wells Fargo & Company lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price target for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Benchmark reaffirmed a "buy" rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and boosted their price objective for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Morgan Stanley upped their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.